TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00262795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil p.o. (0,4 mg - max. 0,8 mg/kg/d, d1) q15d, max. 12 month
Study: NCT01984580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc gluconate
Description: 26.6 mg zinc BID (as zinc gluconate)
Study: NCT03143725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972
Description: Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972
Description: Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972
Description: Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972
Description: Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
Study: NCT03340402

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Proton radiation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlignRT
Description: AlignRTTM uses infrared imaging to capture the 3D data of the patient's position to ensure accuracy of treatment delivery
Study: NCT04073264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monofilament
Description: In the intervention group,monofilament absorbable suture,will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monofilament
Description: In the intervention group,monofilament absorbable suture,will be used.
Study: NCT01463956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-Interferon α-2b or Peg-Interferon α-2a
Description: Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin: capsules 200 mg (weight-based daily dose: \<65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; \>105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
Study: NCT02835339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate 4g loading dose, 1g/hr infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 6g loading dose, 2g/hr infusion
Study: NCT01216111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Cisplatin
Description: Paclitaxel 80 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15~1 cycle = 28days~PC\*6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
Description: fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
Study: NCT01565083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.
Study: NCT03789578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0148-0287sema
Description: Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0148-0287
Description: Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
Study: NCT03723161

Intervention type: DEVICE
Intervention: Bone Achored Hearing surgery
Description: This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected data will be used to assess the implant stability development of the Ponto BHX implant during up tp 24 months after implantation in a pediatric population undergoing bone anchored hearing surgery.
Study: NCT01565083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: A dose of 25 mg/m\^2 followed by 30-35 mg/m\^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: A dose of 25 mg/m\^2 followed by 30-35 mg/m\^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.
Study: NCT02320474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Study: NCT01501799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adapalene 0.1% and benzoyl peroxide 2.5% topical gel
Description: Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPIDUO
Description: EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle Gel)
Description: Vehicle Gel
Study: NCT02946957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Insomnia
Description: Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Only Control
Description: Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
Study: NCT02369003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Nerve Graft
Description: Implantation of Autologous Peripheral Nerve Graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with PD undergoing deep brain stimulation (DBS) surgery.
Study: NCT03229863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweet Potatos
Description: Plum Organics, Just Sweet Potato

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pears
Description: Earth's Best, First Pears
Study: NCT04176419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ketamine
Description: 0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lidocaine
Description: 1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1,000 mg orally at time of check-in to the preoperative unit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acetaminophen
Description: 1,000 mg orally at time of check-in to the preoperative unit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 600 mg orally at time of check in to the preoperative unit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gabapentin
Description: 600 mg orally at time of check in to the preoperative unit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg orally at time of check in to the preoperative unit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Celecoxib
Description: 200 mg orally at time of check in to the preoperative unit
Study: NCT02516566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Mechanical ventilation with PEEP 8 cmH2O
Study: NCT02680795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat IV
Description: Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat IV
Description: Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat IV
Description: Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.
Study: NCT02691897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 3mg once daily at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet once daily at bedtime
Study: NCT00736320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)
Description: chemotherapy with 2 cycles of ABVD (day 1 + 15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)
Description: chemotherapy with 2 cycles of ABVD (day 1 + 15)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 20 Gy IFRT (Involved Field Radiotherapy)
Description: 20 Gy Involved Field Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 20 Gy IFRT (Involved Field Radiotherapy)
Description: 20 Gy Involved Field Radiotherapy
Study: NCT00525109

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study: NCT00598559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.

Intervention type: DRUG
Group type: OTHER
Intervention: IV Acetaminophen
Description: Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
Study: NCT03480711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SST in group (A)
Description: group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trabeculectomy with ESST in group (B)
Description: group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
Study: NCT02261428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter Tiemann
Description: We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction catheter
Description: We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
Study: NCT04675177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol foam sclerotherapy
Description: i. Patients underwent preparation, two hours before the intervention, with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. Preparation of the polidocanol (Aethoxysklerol 3%) foam according to Tessari technique immediately before application, so that the microbubbles of the foam did not disintegrate; iii. The procedure was performed in the medical office. Application according to the Blanchard technique through a disposable transparent anoscope, in jackknife position, using a 20mL disposable syringe of the mixture (polidocanol + air) and a reusable 10 cm syringe extender adapted to an intravenous needle; iv. Patients were treated in a maximum of 3 sessions, at 3 weeks intervals; v. Maximum dose per treatment session of 20mL of mixture of 4mL of polidocanol 3% with 16mL of air; i. In each session, the sclerosant was injected in one or more hemorroidary cushion;

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler-guided hemorrhoidal artery ligation
Description: i. Patients underwent preparation with cleaning enema (Disodium phosphate). No antibiotic prophylaxis was prescribed.~ii. The procedure was performed in the operating room of an outpatient surgery unit, under regional anestesia.~iii. A proctoscope with a Doppler transducer in its tip was introduced inside the anal canal to search for the superior rectal artery.~iv. Each branch was ligated with suture above the dentate line. The device was rotated slowly in clockwise direction to locate further arteries at that level.~v. Rectoanal repair consisted in a continuous running suture was applied longitudinally just over every prolapsed hemorrhoid.
Study: NCT03145532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS plus robotic training
Description: Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS plus robotic training
Description: Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.
Study: NCT01880333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkin Diet
Description: Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children\<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
Study: NCT01811446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle Activation with Niveus and Intelect Devices
Description: Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle Activation with Niveus and Intelect Devices
Description: Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
Study: NCT00133718

Intervention type: DRUG
Group type: OTHER
Intervention: Combined lifestyle intervention and optimisation of pharmacological treatment
Description: 1. 6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~2. standard care

Intervention type: DRUG
Group type: OTHER
Intervention: Combined lifestyle intervention and optimisation of pharmacological treatment
Description: 1. 6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~2. standard care
Study: NCT01053273

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Epidural Injection
Description: Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous adhesiolysis
Description: Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
Study: NCT02355743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rtPA lock therapy
Description: rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion.
Study: NCT02961530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric exercises
Description: The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic eccentric exercises
Description: The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours.
Study: NCT01992679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The BWSTT program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training. Training will take place on a Therastride which consists of a treadmill with an air pressure powered pulley system connected to a harness system. The locomotor training strategy focuses on proper gait mechanics, including weight bearing, shifting and maintaining body positioning. Manipulating the participant's legs is done in such a way as to provide appropriate sensory-motor cues that facilitate the development and refinement of walking pattern.